Constellation Pharmaceuticals Appoints Industry Veteran James E. Audia, Ph.D. as Chief Scientific Officer

-Accomplished Executive Brings Broad Drug Discovery and Development Experience-

CAMBRIDGE, MA – January 4, 2011 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced the appointment of Dr. James E. Audia as Chief Scientific Officer. Audia joins Constellation following a highly productive career in drug discovery at Eli Lilly and Company.

Audia held several key leadership roles during his 23-year tenure at Lilly. As a Distinguished Lilly Scholar, the highest level of the company’s scientific ladder, Audia made seminal technical and strategic contributions to the Lilly drug pipeline. Prior to this role, Audia was Executive Director, Discovery Chemistry Research and Technologies, where he had global responsibility for delivery of small molecule drug candidates across all therapeutic areas. Audia also played a major role in companywide leadership of product strategy and portfolio management for Lilly for more than a decade. Over the course of his career, Audia’s scientific work has contributed to more than 12 development candidates, including transformative contributions to the treatment of Alzheimer’s disease through his discovery of both the first gamma secretase inhibitor and an industry-leading beta secretase inhibitor.

"We are delighted to have Jim join our leadership team at Constellation,” said Mark A. Goldsmith, M.D., Ph.D., President and Chief Executive Officer of Constellation. “He is widely recognized as an industry leader across all aspects of drug discovery and early development, and he brings a deep set of experiences and talents to Constellation at a time of great progress and promise for our lead compounds as they move toward the clinic.”

“Constellation is leading the field in the discovery and development of novel drugs against multiple classes of chromatin regulators implicated in critical therapeutic disease areas such as oncology and inflammation,” said Audia. “I am very pleased to have the opportunity to join this great team in the pursuit of drugs that will have a significant impact for patients.”

Audia is a named inventor on more than 90 issued US patents and has published and presented extensively. Audia received his Ph.D. in Organic Chemistry from the University of South Carolina, and did postdoctoral training at Yale University before joining Lilly.

Constellation also announced that Edward E. Harlow, Jr., Ph.D. has become Constellation Research Fellow, providing continued guidance in the area of cancer biology. Dr. Harlow was recently named Special Assistant to the Director at the National Cancer Institute, and will be working with the Institute on several strategic initiatives in cancer research.

About Constellation Pharmaceuticals
Constellation Pharmaceuticals is a leading biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the emerging field of epigenetics, a new field of science that focuses on chromatin modifiers and the regulation of gene expression. The Company’s academic founders are thought leaders in epigenetics responsible for numerous seminal advances. Constellation Pharmaceuticals is located in Cambridge, Massachusetts. For more information, please visit the company’s website at